Webinar

Beyond "Disease X": Strategic R&D in an Era of Emerging Threats

October 30, 2024 01:00 PM America/New_York

Emerging infectious diseases, like COVID-19 and Ebola, pose an ever-present threat to global health. The World Health Organization's R&D Blueprint is a crucial tool in this ongoing battle, prioritizing research and development for pathogens with the highest potential to cause widespread epidemics. However, limited resources and the specter of unknown "Disease X" threats underscore the urgency and complexity of this task.

Biosynth plays a vital role in this endeavor by providing high-quality raw materials essential for the development of in-vitro diagnostics (IVD). These IVD tests are critical for early detection, surveillance, and containment of infectious diseases. Biosynth's offerings include a vast array of proteins, antibodies, and biospecimens, including reagents for emerging viruses like Monkeypox and Zika. Moreover, our custom manufacturing capabilities and commitment to quality make us a valuable partner for researchers and diagnostic companies working on the front lines of epidemic preparedness. Biosynth's dedication to supporting R&D efforts in infectious diseases highlights the importance of collaboration between industry, academia, and governments to address the complex challenges posed by existing and emerging pathogens.

 

Learning Objectives

  • Understand the current landscape of emerging infectious diseases. Participants should be able to identify key trends, challenges, and opportunities in the field of emerging diseases.

  • Gain insights into the role of diagnostics and biotechnology in combating emerging diseases. Participants should appreciate the importance of rapid and accurate diagnostics, as well as the potential of innovative biotechnological solutions.

  • Explore strategies for preparedness and response to future outbreaks. Participants should be able to discuss the importance of proactive measures and the role of collaboration in mitigating the impact of emerging diseases.

Philip Noone

Chief Commercial Officer

Philip Noone is a seasoned biotechnology executive with over 30 years of experience in the medical diagnostics sector. He specializes in sales, marketing, and innovation, with in-depth knowledge of the biologics market. Currently serving as Chief Commercial Officer at Biosynth, Philip has a proven track record of developing and marketing advanced solutions for infectious diseases and emerging health threats. He is adept at identifying acquisition targets and innovative technologies to drive company growth.

Wayne Hogrefe

Head of Research Projects

With 40+ years in the life sciences, Dr Wayne Hogrefe is an expert in reagents and diagnostics. His areas of expertise are clinical immunology, infectious diseases and emerging infectious diseases. His knowledge spans pharmaceuticals, clinical laboratory services, and in vitro diagnostics, focusing on GLP, quality systems, medical devices, and assay validation. Wayne's leadership at Aalto Bioreagents and current role at Biosynth as Head of Research Products highlights his expertise in in-vitro diagnostics. His Ph.D. in Experimental Pathology and background in immunology and infectious diseases, coupled with extensive experience in the life sciences industry, further solidifies his authority in the field.

Add to calendar